2.51
price down icon4.20%   -0.11
after-market Dopo l'orario di chiusura: 2.50 -0.010 -0.40%
loading
Precedente Chiudi:
$2.62
Aprire:
$2.58
Volume 24 ore:
7.40M
Relative Volume:
1.82
Capitalizzazione di mercato:
$270.43M
Reddito:
-
Utile/perdita netta:
$-258.08M
Rapporto P/E:
-0.9127
EPS:
-2.75
Flusso di cassa netto:
$-202.32M
1 W Prestazione:
-59.97%
1M Prestazione:
-65.52%
6M Prestazione:
-82.56%
1 anno Prestazione:
-88.30%
Intervallo 1D:
Value
$2.40
$2.61
Intervallo di 1 settimana:
Value
$2.19
$2.785
Portata 52W:
Value
$2.19
$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name
Nome
Rocket Pharmaceuticals Inc
Name
Telefono
646-440-9100
Name
Indirizzo
350 FIFTH AVENUE, NEW YORK, NY
Name
Dipendente
299
Name
Cinguettio
@rocketpharma
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
RCKT's Discussions on Twitter

Confronta RCKT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RCKT
Rocket Pharmaceuticals Inc
2.51 675.52M 0 -258.08M -202.32M -2.75
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-27 Downgrade Needham Buy → Hold
2025-05-27 Downgrade TD Cowen Buy → Hold
2025-03-12 Iniziato BMO Capital Markets Outperform
2024-12-30 Iniziato Wedbush Outperform
2024-12-18 Iniziato Jefferies Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-04-02 Iniziato Goldman Neutral
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-02-01 Iniziato Morgan Stanley Overweight
2022-11-08 Iniziato Canaccord Genuity Buy
2022-11-01 Iniziato BTIG Research Buy
2022-07-08 Iniziato Raymond James Outperform
2021-10-20 Ripresa Cowen Outperform
2021-03-02 Iniziato Stifel Buy
2021-02-18 Iniziato Needham Buy
2020-12-16 Iniziato UBS Buy
2020-12-08 Downgrade Oppenheimer Outperform → Perform
2020-07-02 Iniziato JP Morgan Overweight
2020-06-25 Ripresa BofA/Merrill Buy
2020-06-01 Ripresa Oppenheimer Outperform
2019-11-06 Iniziato Chardan Capital Markets Buy
2019-09-26 Iniziato Piper Jaffray Overweight
2019-04-23 Iniziato Robert W. Baird Outperform
2019-03-15 Iniziato BofA/Merrill Buy
2019-02-05 Iniziato Oppenheimer Outperform
2018-09-13 Iniziato Ladenburg Thalmann Buy
2018-07-10 Iniziato William Blair Outperform
Mostra tutto

Rocket Pharmaceuticals Inc Borsa (RCKT) Ultime notizie

pulisher
May 31, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World

May 31, 2025
pulisher
May 31, 2025

Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World

May 31, 2025
pulisher
May 31, 2025

Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Target | RCKT Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider

May 30, 2025
pulisher
May 30, 2025

Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 30, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN

May 29, 2025
pulisher
May 29, 2025

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN

May 29, 2025
pulisher
May 29, 2025

JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com

May 29, 2025
pulisher
May 28, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent

May 28, 2025
pulisher
May 28, 2025

Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 28, 2025

RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amid Clinical Hold | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Receives Downgrade and Price Targe - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade Amid Clinical Tria - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Ca - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Capital | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Challenges After Clinical Hold | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amidst Clin - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Scotiabank cuts Rocket Pharmaceuticals target to $19 - Investing.com

May 28, 2025
pulisher
May 28, 2025

Chardan Cuts Price Target on Rocket Pharmaceuticals to $17 From $46, Keeps Buy Rating - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga

May 28, 2025
pulisher
May 28, 2025

Jefferies Downgrades Rocket Pharmaceuticals (RCKT) Rating and Pr - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Setback Amid Clinical Trial Death | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Needham Downgrades Rocket Pharmaceuticals to Hold From Buy - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA H - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA Hold | RCKT Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Morgan Stanley cuts Rocket Pharmaceuticals stock rating, slashes PT - Investing.com

May 28, 2025
pulisher
May 28, 2025

Jefferies cuts Rocket Pharmaceuticals stock rating, slashes target - Investing.com

May 28, 2025
pulisher
May 28, 2025

Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery - Investing.com India

May 28, 2025

Rocket Pharmaceuticals Inc Azioni (RCKT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):